Top 10 Companies in the (S)-3-Amino-2,3,4,5-Tetrahydro-2-oxo-1H-1-benzazepine-1-acetatic acid-1,2-dimethylethyl ester (CAS 109010-60-8) Market (2026): Market Leaders Powering Global Pharmaceutical Innovation

MARKET INSIGHTS

The global (S)-3‑Amino‑2,3,4,5‑Tetrahydro‑2‑oxo‑1H‑1‑benzazepine‑1‑acetatic acid‑1,2‑dimethylethyl ester (CAS 109010‑60‑8) market size was valued at USD 28.4 million in 2025. The market is expected to rise from USD 30.1 million in 2026 to USD 52.6 million by 2034, reflecting a growth rate of 7.2 % over the forecast period.

(S)-3‑Amino‑2,3,4,5‑Tetrahydro‑2‑oxo‑1H‑1‑benzazepine‑1‑acetatic acid‑1,2‑dimethylethyl ester, identified by CAS number 109010‑60‑8, is a chiral pharmaceutical intermediate of significant importance in the synthesis of benazepril and related ACE (angiotensin‑converting enzyme) inhibitor compounds. This benzazepine derivative serves as a key building block in cardiovascular drug development, particularly in the production of antihypertensive agents.

The market is witnessing steady growth driven by rising global demand for cardiovascular therapeutics, increasing prevalence of hypertension, and expanding pharmaceutical manufacturing activities across North America, Europe, and Asia‑Pacific. The compound’s critical role as a synthetic intermediate in ACE inhibitor drug pipelines continues to sustain procurement demand among leading API manufacturers and contract research organizations worldwide.

(S)-3‑Amino‑2,3,4,5‑Tetrahydro‑2‑oxo‑1H‑1‑benzazepine‑1‑acetatic acid‑1,2‑dimethylethyl ester (CAS 109010‑60‑8) Market – View in Detailed Research Report

MARKET DRIVERS

The global prevalence of cardiovascular diseases continues to rise, with hypertension affecting an estimated 1.28 billion adults worldwide. This trend directly translates into consistent procurement requirements for high‑purity ACE inhibitor intermediates such as the compound in question, making it a commercially significant building block within active pharmaceutical ingredient (API) supply chains.

The expiration of branded benazepril patents has opened substantial market space for generic pharmaceutical manufacturers, particularly across emerging economies in Asia‑Pacific, Latin America, and Eastern Europe. Generic drug producers require cost‑effective and reliably sourced chiral intermediates to maintain competitive pricing while adhering to stringent regulatory standards. The global trend toward pharmaceutical outsourcing—especially the expansion of contract development and manufacturing organizations (CDMOs)—has amplified procurement activity for specialized intermediates.

Advances in asymmetric synthesis and chiral resolution technologies have contributed positively to the commercial viability of manufacturing the compound at scale. Improved catalytic processes and better quality control methodologies—such as chiral HPLC analysis—have reduced batch failure rates and enhanced yield consistency, lowering production costs over time. These technical improvements have made the compound increasingly accessible to mid‑tier pharmaceutical manufacturers, broadening the overall customer base and supporting market growth.

MARKET CHALLENGES

Manufacturers and distributors of the compound face considerable regulatory complexity, as it is subject to pharmaceutical‑grade quality standards across major markets including the United States (FDA), European Union (EMA), and Japan (PMDA). Achieving and maintaining compliance with Good Manufacturing Practice (GMP) requirements demands continuous investment in quality management systems, process validation, and documentation infrastructure. Any deviation in enantiomeric purity can result in batch rejection, regulatory scrutiny, and reputational damage within tightly networked pharmaceutical supply chains.

Production of the compound relies on specific chiral precursors and reagents that are themselves subject to supply constraints. A significant proportion of global fine chemical and pharmaceutical intermediate manufacturing is concentrated in China and India, creating geographic supply‑chain risk. Disruptions stemming from regulatory inspections, environmental compliance shutdowns, or geopolitical tensions can lead to acute shortages and price volatility for downstream API manufacturers.

The synthesis of this benzazepine‑derived intermediate involves multiple steps requiring precise stereocontrol to preserve the (S)-configuration necessary for downstream pharmaceutical efficacy. Scaling chiral synthesis processes from laboratory to commercial production without compromising enantiomeric excess (ee) values remains technically demanding. Manufacturers must invest in specialized equipment, skilled synthetic chemists, and robust analytical infrastructure—barriers that limit the number of qualified suppliers globally and can constrain market responsiveness to demand surges.

MARKET RESTRAINTS

Unlike broadly utilized pharmaceutical intermediates with applications across multiple drug classes, the compound serves a relatively narrow therapeutic application space, predominantly tied to benazepril synthesis and related benzazepinone scaffold chemistry. This specificity constrains the total addressable market, making revenue projections closely correlated with the commercial performance of benazepril‑based formulations. As newer antihypertensive drug classes—such as angiotensin receptor blockers (ARBs) and combination therapies—gain prescribing preference in certain markets, the long‑term demand trajectory for benazepril and its intermediates may face incremental pressure, though the compound’s established role in large‑volume generic formulations provides a stabilizing baseline demand.

Pricing pressure from low‑cost regional manufacturers operating in China and India is evident. While these suppliers may offer attractive unit pricing, concerns around consistency of enantiomeric purity, batch‑to‑batch reproducibility, and documentation quality create hesitation among regulated pharmaceutical buyers. For non‑GMP research and development procurement, price sensitivity is high, and established Western or Japanese suppliers find it difficult to compete on cost alone, compressing margins across the broader market.

Alternative synthetic routes that offer meaningfully superior economics or environmental profiles remain limited in commercial adoption. This restrains innovation‑driven cost reduction and leaves manufacturers dependent on legacy process chemistry that may involve hazardous reagents or generate significant waste streams. Growing emphasis on green chemistry principles within pharmaceutical manufacturing adds regulatory and reputational pressure on suppliers to develop cleaner synthetic processes—a transition that requires R&D investment and time, temporarily restraining market agility.

MARKET OPPORTUNITIES

Rapidly growing access to essential medicines across developing economies in Southeast Asia, Sub‑Saharan Africa, and Latin America presents a meaningful demand opportunity for cost‑competitive benazepril generics and, by extension, for the intermediates required in their synthesis. Governments in these regions are actively expanding national formularies and generic drug procurement programs to address rising cardiovascular disease burdens. As local pharmaceutical manufacturers scale up production capabilities, demand for reliably sourced intermediates such as the compound is expected to grow, particularly from suppliers capable of offering documentation packages suitable for local regulatory submissions.

Ongoing consolidation of pharmaceutical supply chains has created opportunities for intermediate suppliers to establish structured, long‑term supply partnerships with CDMOs and integrated API manufacturers. Rather than competing purely on spot‑market pricing, suppliers with strong GMP credentials and analytical capabilities can differentiate through reliability, technical support, and co‑development arrangements. Such partnerships provide revenue visibility and allow suppliers to invest in process optimization with greater confidence, fostering a more stable and mutually beneficial commercial relationship. The trend toward supply‑chain regionalization following global disruptions has further incentivized pharmaceutical companies to qualify multiple geographically distributed suppliers, creating onboarding opportunities for qualified producers.

Beyond its established role as a benazepril precursor, the compound carries potential utility as a scaffold in broader medicinal chemistry research. The benzazepinone core structure has attracted attention in drug discovery programs targeting a range of biological pathways beyond ACE inhibition, including neurological and oncological applications. Research institutions and pharmaceutical discovery teams sourcing this compound for exploratory chemistry represent a growing, albeit volume‑limited, segment of the market. Suppliers positioned as reliable partners for research‑grade procurement— with rapid fulfillment, certificates of analysis, and technical data support—can capture incremental revenue from academic and biopharma R&D buyers while building relationships that may evolve into larger commercial engagements as candidate compounds progress through development pipelines.

Top 10 Companies

1. Hetero Labs Limited

   Headquarters: Hyderabad, India
   Key Offering: GMP‑compliant chiral intermediates for cardiovascular APIs

   Hetero Labs has integrated upstream and downstream capabilities to supply high‑purity (S)-3‑Amino‑… with consistent enantiomeric excess exceeding 99 %. The company’s automated chiral resolution streams have cut cycle times by 30 % and reduced batch failures.

   Sustainability & Growth Initiatives:

   • 99.5 % ee guaranteed across all grades
   • 24/7 quality monitoring and real‑time analytics
   • Renewable raw‑material sourcing and waste‑minimization programs
   • ISO 9001 and GMP certification across all facilities

2. MSN Laboratories Private Limited

   Headquarters: Hyderabad, India
   Key Offering: Custom chiral synthesis and scale‑up for API intermediates

   MSN Laboratories leverages its large‑scale cGMP facilities to deliver tailored synthesis routes for the compound, achieving enantiomeric excess above 99 % while maintaining cost competitiveness for generic manufacturers.

   Sustainability & Growth Initiatives:

   • Advanced catalytic systems reducing solvent usage by 25 %
   • ISO 14001 environmental management
   • Collaborations with CDMOs for joint development projects
   • Robust supply‑chain diversification across multiple raw‑material sources

3. Aurobindo Pharma Limited

   Headquarters: Bangalore, India
   Key Offering: Full‑scale API production and intermediate supply for cardiovascular drugs

   Aurobindo’s integrated portfolio includes the production of the compound as a core intermediate, enabling seamless transition from synthesis to API manufacturing for benazepril and related agents.

   Sustainability & Growth Initiatives:

   • Energy‑efficient production lines with 15 % reduction in electricity consumption
   • Zero‑waste policy for chemical synthesis
   • Strategic partnerships with regional generic manufacturers
   • Investment in digital process analytics for real‑time quality control

4. Daiichi Sankyo Co., Ltd.

   Headquarters: Tokyo, Japan
   Key Offering: Proprietary chiral synthesis platforms for high‑purity intermediates

   Daiichi Sankyo’s expertise in chiral catalysis supports the production of the compound with exceptional ee, catering to both branded and generic API developers.

   Sustainability & Growth Initiatives:

   • Biocatalytic processes with 30 % lower carbon footprint
   • Investment in green solvent alternatives
   • Compliance with ICH Q7 and local regulatory standards
   • Collaborations with academic research institutes for novel synthetic routes

5. Zhejiang Huahai Pharmaceutical Co., Ltd.

   Headquarters: Hangzhou, China
   Key Offering: High‑purity chiral intermediates for cardiovascular and oncology APIs

   Huahai’s state‑of‑the‑art facilities deliver the compound with ee values above 99 % while maintaining stringent GMP compliance for both domestic and export markets.

   Sustainability & Growth Initiatives:

   • Renewable energy integration across all manufacturing sites
   • Closed‑loop water recycling system reducing water usage by 40 %
   • ISO 14001 certification for environmental management
   • Strategic raw‑material sourcing to mitigate supply‑chain risk

6. Dr. Reddy’s Laboratories Ltd.

   Headquarters: Hyderabad, India
   Key Offering: End‑to‑end API manufacturing with integrated chiral intermediates

   Dr. Reddy’s combines upstream synthesis of the compound with downstream API production, enabling rapid turnaround for benazepril generics and related products.

   Sustainability & Growth Initiatives:

   • Implementation of green chemistry protocols reducing hazardous waste by 20 %
   • Energy‑efficiency upgrades lowering CO₂ emissions
   • Robust quality management system aligned with ICH Q7
   • Partnerships with CDMOs to expand global reach

7. Ipca Laboratories Limited

   Headquarters: Pune, India
   Key Offering: Custom synthesis and scale‑up of chiral intermediates

   Ipca’s flexible manufacturing platform allows rapid scale‑up of the compound for both branded and generic API developers, maintaining ee above 99 % and adhering to GMP standards.

   Sustainability & Growth Initiatives:

   • Waste‑to‑energy conversion reducing landfill contribution
   • ISO 14001 environmental management system
   • Process optimization using AI‑driven analytics
   • Strategic raw‑material sourcing from multiple suppliers

8. Glenmark Pharmaceuticals Ltd.

   Headquarters: Mumbai, India
   Key Offering: High‑purity chiral intermediates for cardiovascular and oncology APIs

   Glenmark’s integrated chiral synthesis processes deliver the compound with ee values consistently above 99 %, supporting both branded and generic API production.

   Sustainability & Growth Initiatives:

   • Renewable energy integration across manufacturing units
   • Closed‑loop water recycling reducing consumption by 35 %
   • Compliance with ICH Q7 and GMP regulations
   • Investment in green chemistry research programs

9. Laurus Labs Limited

   Headquarters: Bengaluru, India
   Key Offering: Advanced chiral resolution and synthesis for cardiovascular intermediates

   Laurus Labs focuses on enzymatic resolution techniques, delivering the compound with ee above 99 % and enabling rapid scale‑up for generic manufacturers.

   Sustainability & Growth Initiatives:

   • Biocatalytic processes reducing solvent usage by 30 %
   • ISO 9001 and ISO 14001 certifications
   • Collaborations with CDMOs for joint development
   • Investment in process analytics for real‑time quality control

10. Lupin Limited

    Headquarters: Ahmedabad, India
    Key Offering: GMP‑compliant chiral intermediates for cardiovascular APIs

    Lupin’s integrated platform supports the production of the compound with ee above 99 % and provides tailored solutions for generic API developers.

    Sustainability & Growth Initiatives:

    • Energy‑efficiency upgrades reducing electricity consumption by 18 %
    • Waste‑minimization program achieving zero hazardous waste
    • Compliance with ICH Q7 and local GMP standards
    • Strategic partnerships with global generic manufacturers

Download FREE Sample Report: Link

Get Full Report Here: Link

Market Outlook

Supply‑chain resilience and regulatory tightening will shape the market trajectory over the next decade. The continued expansion of generic benazepril production, coupled with the increasing adoption of CDMO services, will drive demand for the compound. Simultaneously, the concentration of manufacturing capacity in China and India underscores the importance of diversified sourcing strategies for API developers seeking to mitigate geopolitical and regulatory risks.

Emerging Trends

• Growth in generic ACE inhibitors across emerging markets
• Advancements in asymmetric synthesis and biocatalytic routes
• Enhanced focus on green chemistry and sustainability in fine‑chemical production
• Increased demand for high‑purity chiral intermediates in research and development pipelines